R. F. Wang and S. A. Rosenberg, Human tumor antigens for cancer vaccine development, Immunol. Rev, vol.170, pp.85-100, 1999.

N. Renkvist, C. Castelli, P. F. Robbins, and G. Parmiani, A listing of human tumor antigens recognized by T cells, Cancer Immunol. Immunother, vol.50, pp.3-15, 2001.

M. J. Scanlan, A. J. Simpson, and L. J. Old, The cancer/testis genes: review, standardization, and commentary, Cancer Immun, vol.4, p.1, 2004.

D. Valmori, V. Dutoit, D. Lienard, F. Lejeune, D. Speiser et al., Tetramer-guided analysis of TCR beta-chain usage reveals a large repertoire of melan-A-specific CD8 + T cells in melanoma patients, J. Immunol, vol.165, pp.533-538, 2000.

S. Mocellin, S. Mandruzzato, V. Bronte, M. Lise, and D. Nitti, Part I: Vaccines for solid tumours, Lancet Oncol, vol.5, pp.681-689, 2004.

C. Scheibenbogen, A. Letsch, A. Schmittel, A. M. Asemissen, E. Thiel et al., Rational peptide-based tumour vaccine development and T cell monitoring, Semin. Cancer Biol, vol.13, pp.423-429, 2003.

D. Valmori, J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard et al., Enhanced generation of specific tumorreactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues, J. Immunol, vol.160, pp.1750-1758, 1998.

A. B. Bakker, S. H. Van-der-burg, R. J. Huijbens, J. W. Drijfhout, C. J. Melief et al., Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope, Int. J. Cancer, vol.70, pp.302-309, 1997.

D. Valmori, J. F. Fonteneau, S. Valitutti, N. Gervois, R. Dunbar et al., Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues, Int. Immunol, vol.11, pp.1971-1980, 1999.

E. R. Christinck, M. A. Luscher, B. H. Barber, and D. B. Williams, Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis, Nature, vol.352, pp.67-70, 1991.

C. V. Harding and E. R. Unanue, Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T cell stimulation, Nature, vol.346, pp.574-576, 1990.

V. Dutoit, V. Rubio-godoy, P. Y. Dietrich, A. L. Quiqueres, V. Schnuriger et al., Heterogeneous T cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity, Cancer Res, vol.61, pp.5850-5856, 2001.

T. N. Bullock, D. W. Mullins, T. A. Colella, and V. H. Engelhard, Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class Itransgenic mice, J. Immunol, vol.167, pp.5824-5831, 2001.

J. H. Kessler, B. Mommaas, T. Mutis, I. Huijbers, D. Vissers et al., Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluoresceinlabeled synthetic peptides, Hum. Immunol, vol.64, pp.245-255, 2003.

A. Sette, J. Sidney, M. F. Del-guercio, S. Southwood, J. Ruppert et al., Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays, Mol. Immunol, vol.31, pp.813-822, 1994.

T. N. Bullock, T. A. Colella, and V. H. Engelhard, The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice, J. Immunol, vol.164, pp.2354-2361, 2000.

T. N. Bullock, D. W. Mullins, and V. H. Engelhard, Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8 + T cells, J. Immunol, vol.170, pp.1822-1829, 2003.

C. J. Cohen, G. Denkberg, A. Lev, M. Epel, and Y. Reiter, Recombinant antibodies with MHC-restricted, peptide-specific, T cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions, J. Mol. Recognit, vol.16, pp.324-332, 2003.

R. A. Willemsen, R. Debets, P. Chames, and R. L. Bolhuis, Genetic engineering of T cell specificity for immunotherapy of cancer, Hum. Immunol, vol.64, pp.56-68, 2003.

P. Van-der-bruggen, J. Bastin, T. Gajewski, P. G. Coulie, P. Boel et al., A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3, Eur. J. Immunol, vol.24, pp.3038-3043, 1994.

A. Scheffold, S. Miltenyi, and A. Radbruch, Magnetofluorescent liposomes for increased sensitivity of immunofluorescence, Immunotechnology, vol.1, pp.127-137, 1995.

E. Keogh, J. Fikes, S. Southwood, E. Celis, R. Chesnut et al., Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity, J. Immunol, vol.167, pp.787-796, 2001.

H. T. Khong and S. A. Rosenberg, Pre-existing immunity to tyrosinaserelated protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy, J. Immunol, vol.168, pp.951-956, 2002.

M. J. Palmowski, L. Lopes, Y. Ikeda, M. Salio, V. Cerundolo et al., Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response, J. Immunol, vol.172, pp.1582-1587, 2004.

G. Held, M. Matsuo, M. Epel, S. Gnjatic, G. Ritter et al., Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments, Eur. J. Immunol, vol.34, pp.2919-2929, 2004.

G. Denkberg, E. Klechevsky, and Y. Reiter, Modification of a tumorderived peptide at an HLA-A2 anchor residue can alter the conformation of the MHC-peptide complex: probing with TCR-like recombinant antibodies, J. Immunol, vol.169, pp.4399-4407, 2002.

P. D. Holler, L. K. Chlewicki, and D. M. Kranz, TCRs with high affinity for foreign pMHC show self-reactivity, Nat. Immunol, vol.4, pp.55-62, 2003.

A. K. Sharma, J. J. Kuhns, S. Yan, R. H. Friedline, B. Long et al., Class I major histocompatibility complex anchor substitutions alter the conformation of T cell receptor contacts, J. Biol. Chem, vol.276, pp.21443-21449, 2001.

K. R. Ryan, L. K. Mcneil, C. Dao, P. E. Jensen, and B. D. Evavold, Modification of peptide interaction with MHC creates TCR partial agonists, Cell. Immunol, vol.227, pp.70-78, 2004.

S. Yang, G. P. Linette, S. Longerich, and F. G. Haluska, Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2 M is correlated to TCR avidity, J. Immunol, vol.169, pp.531-539, 2002.

M. A. Purbhoo, D. J. Irvine, J. B. Huppa, and M. M. Davis, T cell killing does not require the formation of a stable mature immunological synapse, Nat. Immunol, vol.5, pp.524-530, 2004.

K. C. Garcia, M. Degano, R. L. Stanfield, A. Brunmark, M. R. Jackson et al., An alphabeta T cell receptor structure at 2.5 and its orientation in the TCR-MHC complex, Science, vol.274, pp.209-219, 1996.

W. E. Biddison, R. V. Turner, S. J. Gagnon, A. Lev, C. J. Cohen et al., Tax and M1 peptide/HLA-A2-specific Fabs and T cell receptors recognize nonidentical structural features on peptide/HLA-A2 complexes, J. Immunol, vol.171, pp.3064-3074, 2003.

G. Denkberg, C. J. Cohen, and Y. Reiter, Critical role for CD8 in binding of MHC tetramers to TCR: CD8 antibodies block specific binding of human tumor-specific MHC-peptide tetramers to TCR, J. Immunol, vol.167, pp.270-276, 2001.

P. D. Holler and D. M. Kranz, Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation, Immunity, vol.18, pp.255-264, 2003.

C. J. Cohen, O. Sarig, Y. Yamano, U. Tomaru, S. Jacobson et al., Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies, J. Immunol, vol.170, pp.4349-4361, 2003.

M. F. Princiotta, D. Finzi, S. B. Qian, J. Gibbs, S. Schuchmann et al., Quantitating protein synthesis, degradation, and endogenous antigen processing, Immunity, vol.18, pp.343-354, 2003.

P. A. Reay, K. Matsui, K. Haase, C. Wulfing, Y. H. Chien et al., Determination of the relationship between T cell responsiveness and the number of MHC-peptide complexes using specific monoclonal antibodies, J. Immunol, vol.164, pp.5626-5634, 2000.

C. J. Cohen, N. Hoffmann, M. Farago, H. R. Hoogenboom, L. Eisenbach et al., Direct detection and quantitation of a distinct T cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells, Cancer Res, vol.62, pp.5835-5844, 2002.

A. Porgador, J. W. Yewdell, Y. Deng, J. R. Bennink, and R. N. Germain, Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody, Immunity, vol.6, pp.715-726, 1997.

E. Jaeger, H. Bernhard, P. Romero, M. Ringhoffer, M. Arand et al., Generation of cytotoxic T cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens, Int. J. Cancer, vol.66, pp.162-169, 1996.

M. R. Marwali, M. A. Macleod, D. N. Muzia, and F. Takei, Lipid rafts mediate association of LFA-1 and CD3 and formation of the immunological synapse of CTL, J. Immunol, vol.173, pp.2960-2967, 2004.

D. N. Garboczi, D. T. Hung, and D. C. Wiley, HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides, Proc. Natl. Acad. Sci, vol.89, pp.3429-3433, 1992.

H. Vie, S. Chevalier, R. Garand, J. P. Moisan, V. Praloran et al., Clonal expansion of lymphocytes bearing the gamma delta T cell receptor in a patient with large granular lymphocyte disorder, Blood, vol.74, pp.285-290, 1989.

R. J. Robb, A. Munck, and K. A. Smith, T cell growth factor receptors. Quantitation, specificity, and biological relevance, J. Exp. Med, vol.154, pp.1455-1474, 1981.